Efficacy of Anti-IL6-Receptor Tocilizumab in Refractory Cystoid Macular Edema of Birdshot Retinochoroidopathy Report of Two Cases and Literature Review

REFERENCES

• Shah KH, Levinson RD, Yu F, et al. Birdshot chorioretinopathy. Surv Ophthalmol. 2005;50:519–541.
   PubMed Web of Science ®Google Scholar
• Vitale AT. Birdshot retinochoroidopathy. J Ophthalmic Vis Res. 2014;9:350–361.
   PubMedGoogle Scholar
• Levinson RD, Brezin A, Rothova A, et al. Research criteria for the diagnosis of birdshot chorioretinopathy: results of an International Consensus Conference. Am J Ophthalmol. 2006;141:185–187.
   Google Scholar
• Zamecki KJ, Jabs DA. HLA typing in uveitis: use and misuse. Am J Ophthalmol. 2010;149:189–193.
   PubMed Web of Science ®Google Scholar
• Menezo V, Taylor SR. Birdshot uveitis: current and emerging treatment options. Clin Ophthalmol. 2014;8:73–81.
   PubMedGoogle Scholar
• Thorne JE, Jabs DA, Peters GB, et al. Birdshot retinochoroidopathy: ocular complications and visual impairment. Am J Ophthalmol. 2005;140:45–51.
   PubMed Web of Science ®Google Scholar
• Papadia M, Herbort CP. Reappraisal of birdshot retinochoroiditis (BRC): a global approach. Graefes Arch Clin Exp Ophthalmol. 2013;251:861–869.
   PubMed Web of Science ®Google Scholar
• Monnet D, Levinson RD, Holland GN, et al. Longitudinal cohort study of patients with birdshot chorioretinopathy. III. Macular imaging at baseline. Am J Ophthalmol. 2007;144:818–828.
   PubMed Web of Science ®Google Scholar
• Taylor SR, Lightman SL, Sugar EA, et al. The impact of macular edema on visual function in intermediate, posterior and panuveitis. Ocul Immunol Inflamm. 2012;20:171–181.
   PubMed Web of Science ®Google Scholar
• Vitale AT, Rodriguez A, Foster CS. Low-dose cyclosporine therapy in the treatment of birdshot retinochoroidopathy. Ophthalmology. 1994;101:822–831.
   PubMed Web of Science ®Google Scholar
• Kiss S, Ahmed M, Letko E, Foster CS. Long-term follow-up of patients with birdshot retinochoroidopathy treated with corticosteroid-sparing systemic immunomodulatory therapy. Ophthalmology. 2005;112:1066–1071.
   PubMed Web of Science ®Google Scholar
• Thorne JE, Jabs DA, Kedhar SR, et al. Loss of visual field among patients with birdshot chorioretinopathy. Am J Ophthalmol. 2008;145:23–28.
   PubMed Web of Science ®Google Scholar
• Becker MD, Wertheim MS, Smith JR, Rosenbaum JT. Long-term follow-up of patients with birdshot retinochoroidopathy treated with systemic immunosuppression. Ocul Immunol Inflamm. 2005;13:289–293.
   PubMed Web of Science ®Google Scholar
• Cervantes-Castañeda RA, Gonzalez-Gonzalez LA, Cordero-Coma M, et al. Combined therapy of cyclosporine A and mycophenolate mofetil for the treatment of birdshot retinochoroidopathy: a 12-month follow-up. Br J Ophthalmol. 2013;97:637–643.
   PubMed Web of Science ®Google Scholar
• Levy-Clarke G, Jabs DA, Read RW, et al. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmology. 2014;121:785–796.
   PubMed Web of Science ®Google Scholar
• Perez VL, Papaliodis GN, Chu D, et al. Elevated levels of interleukin 6 in the vitreous fluid of patients with pars planitis and posterior uveitis: the Massachusetts eye and ear experience and review of previous studies. Ocul Immunol Inflamm. 2004;12:193–201.
   PubMed Web of Science ®Google Scholar
• Muselier A, Bielefeld P, Bidot S, et al. Efficacy of tocilizumab in two patients with anti-TNF-alpha refractory uveitis. Ocul Immunol Inflamm. 2011;19:382–383.
   PubMed Web of Science ®Google Scholar
• Adán A, Mesquida M, Llorenç V, et al. Tocilizumab treatment for refractory uveitis-related cystoid macular edema. Graefes Arch Clin Exp Ophthalmol. 2013;251:2627–2632.
   PubMed Web of Science ®Google Scholar
• Riancho-Zarrabeitia L, Calvo-Río V, Blanco R, et al. Anti-TNF-α therapy in refractory uveitis associated with sarcoidosis: Multicenter study of 17 patients. Semin Arthritis Rheum. 2015;45:361–368.
   PubMed Web of Science ®Google Scholar
• Calvo-Río V, de la Hera D, Blanco R, et al. Golimumab in uveitis previously treated with other anti-TNF-alpha drugs: a retrospective study of three cases from a single centre and literature review. Clin Exp Rheumatol. 2014;32:864–868.
   PubMed Web of Science ®Google Scholar
• Calvo-Río V, de la Hera D, Beltrán-Catalán E, et al. Tocilizumab in uveitis refractory to other biologic drugs: a study of 3 cases and a literature review. Clin Exp Rheumatol. 2014;32:S54–S57.
   PubMed Web of Science ®Google Scholar
• Calvo-Río V, Blanco R, Beltrán E, et al. Anti-TNF-α therapy in patients with refractory uveitis due to Behçet’s disease: a 1-year follow-up study of 124 patients. Rheumatology (Oxford). 2014;53:2223–2231.
   PubMed Web of Science ®Google Scholar
• Santos-Gómez M, Calvo-Río V, Blanco R, et al. The effect of biologic therapy different from infliximab or adalimumab in patients with refractory uveitis due to Behçet’s disease: results of a multicentre open-label study. Clin Exp Rheumatol. 2016. [Epub ahead of print].
   Web of Science ®Google Scholar
• Calvo-Río V, Blanco R, Santos-Gómez M, et al. Golimumab in refractory uveitis related to spondyloarthritis. Multicenter study of 15 patients. Semin Arthritis Rheum. 2016; 46:95–101.
   PubMed Web of Science ®Google Scholar
• Jabs DA, Nussenblatt RB, Rosenbaum JT; Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. J Ophthalmol. 2005;140:509–516.
   PubMed Web of Science ®Google Scholar
• Baughman RP, Bradley DA, Lower EE. Infliximab in chronic ocular inflammation. Int J Clin Pharmacol Ther. 2005;43:7–11.
   PubMed Web of Science ®Google Scholar
• Lindstedt EW, Baarsma GS, Kuijpers RW, van Hagen PM. Anti-TNF-alpha therapy for sight threatening uveitis. Br J Ophthalmol. 2005;89:533–536.
   PubMed Web of Science ®Google Scholar
• Suhler EB, Smith JR, Wertheim MS, et al. A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes. Arch Ophthalmol. 2005;123:903–912.
   PubMed Web of Science ®Google Scholar
• Díaz-Llopis M, Salom D, Garcia-de-Vicuña C, et al. Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients. Ophthalmology. 2012;119:1575–1581.
   PubMed Web of Science ®Google Scholar
• Tanaka T, Ogata A, Narazaki M. Tocilizumab for the treatment of rheumatoid arthritis. Expert Rev Clin Immunol. 2010;6:843–854.
   PubMed Web of Science ®Google Scholar
• Barbi J, Pardoll D, Pan F. Metabolic control of the Treg/Th17 axis. Immunol Rev. 2013;252:52–77.
   PubMed Web of Science ®Google Scholar
• Kuiper JJ, Mutis T, de Jager W, et al. Intraocular interleukin-17 and proinflammatory cytokines in HLA-A29-associated birdshot chorioretinopathy. Am J Ophthalmol. 2011;152:177–182.
   PubMed Web of Science ®Google Scholar
• Hirano T, Ohguro N, Hohki S, et al. A case of Behçet’s disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab. Mod Rheumatol. 2012;22:298–302.
   PubMed Web of Science ®Google Scholar
• Tappeiner C, Heinz C, Ganser G, Heiligenhaus A. Is tocilizumab an effective option for treatment of refractory uveitis associated with juvenile idiopathic arthritis? J Rheumatol. 2012;39:1294–1295.
   PubMed Web of Science ®Google Scholar
• Oshitari T, Kajita F, Tobe A, et al. Refractory uveitis in patient with Castleman disease successfully treated with tocilizumab. Case Rep Ophthalmol Med. 2012;2012:968180.
   PubMedGoogle Scholar